Drug search by name

Acyclovir Buccal Tablets and Neurotoxicity

Result of checking the interaction of drug Acyclovir Buccal Tablets and disease Neurotoxicity for safety when used together.

Check result:

Acyclovir Buccal Tablets <> Neurotoxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma. Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.

References:

Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988): 385-8
Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985): 362-5
Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993): 507-11
Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994): 460-3
Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986): 892
MacDiarmaid-Gordon AR, O'Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992): 280-3
Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993): 36-9
"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc, Morgantown, WV.
Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984): 920
Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983): 921-5
Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988): 158-63
Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990): 300-1